70 related articles for article (PubMed ID: 15262119)
1. Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients.
Taylor DD; Edwards RP; Case CR; Gerçel-Taylor C
Gynecol Oncol; 2004 Jul; 94(1):54-60. PubMed ID: 15262119
[TBL] [Abstract][Full Text] [Related]
2. HSP-10 in ovarian cancer: expression and suppression of T-cell signaling.
Akyol S; Gercel-Taylor C; Reynolds LC; Taylor DD
Gynecol Oncol; 2006 Jun; 101(3):481-6. PubMed ID: 16386781
[TBL] [Abstract][Full Text] [Related]
3. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors.
Taylor DD; Gerçel-Taylor C; Lyons KS; Stanson J; Whiteside TL
Clin Cancer Res; 2003 Nov; 9(14):5113-9. PubMed ID: 14613988
[TBL] [Abstract][Full Text] [Related]
4. Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients.
Taylor DD; Bender DP; Gerçel-Taylor C ; Stanson J; Whiteside TL
Br J Cancer; 2001 Jun; 84(12):1624-9. PubMed ID: 11401315
[TBL] [Abstract][Full Text] [Related]
5. CD3 zeta expression of regional lymph node and peripheral blood lymphocytes in gastric cancer.
Ishigami S; Natsugoe S; Miyazono F; Tokuda K; Nakajo A; Matsumoto M; Okumura H; Nakashima S; Hokita S; Maruyama I; Aikou T
Anticancer Res; 2004; 24(3b):2123-6. PubMed ID: 15274412
[TBL] [Abstract][Full Text] [Related]
6. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.
Lokshin AE; Winans M; Landsittel D; Marrangoni AM; Velikokhatnaya L; Modugno F; Nolen BM; Gorelik E
Gynecol Oncol; 2006 Aug; 102(2):244-51. PubMed ID: 16434085
[TBL] [Abstract][Full Text] [Related]
7. Expression of zeta in T cells prior to interleukin-2 therapy as a predictor of response and survival in patients with ovarian carcinoma.
Kuss I; Rabinowich H; Gooding W; Edwards R; Whiteside TL
Cancer Biother Radiopharm; 2002 Dec; 17(6):631-40. PubMed ID: 12537666
[TBL] [Abstract][Full Text] [Related]
8. Effect of hydralazine on CD3-zeta chain expression in Jurkat T cells.
Januchowski R; Jagodziński PP
Adv Med Sci; 2006; 51():178-80. PubMed ID: 17357303
[TBL] [Abstract][Full Text] [Related]
9. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
[TBL] [Abstract][Full Text] [Related]
10. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425
[TBL] [Abstract][Full Text] [Related]
11. Disseminated tumor cells in peripheral blood: a novel marker for therapy response in locally advanced rectal cancer patients undergoing preoperative chemoradiation.
Zitt M; Zitt M; Müller HM; Dinnewitzer AJ; Schwendinger V; Goebel G; De Vries A; Amberger A; Weiss H; Margreiter R; Ofner D; Oberwalder M
Dis Colon Rectum; 2006 Oct; 49(10):1484-91. PubMed ID: 17019657
[TBL] [Abstract][Full Text] [Related]
12. Modulation of T-cell CD3-zeta chain expression during normal pregnancy.
Taylor DD; Sullivan SA; Eblen AC; Gercel-Taylor C
J Reprod Immunol; 2002 Mar; 54(1-2):15-31. PubMed ID: 11839393
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib up-regulates the expression of the zeta chain of T cell receptor complex in tumor-infiltrating lymphocytes in human cervical cancer.
Ferrandina G; Ranelletti FO; Legge F; Salutari V; Martinelli E; Fattorossi A; Lorusso D; Zannoni G; Vellone V; Paglia A; Scambia G
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2055-60. PubMed ID: 16609015
[TBL] [Abstract][Full Text] [Related]
15. [Expression of zeta (zeta) chain in peripheral blood T lymphocytes and NK cells of children with idiopathic nephrotic syndrome (INS)--preliminary results].
Musiał K; Ciszak L; Kosmaczewska A; Szteblich A; Pawlak E; Zwolińska D; Frydecka I
Przegl Lek; 2006; 63 Suppl 3():208-10. PubMed ID: 16898532
[TBL] [Abstract][Full Text] [Related]
16. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
17. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
[TBL] [Abstract][Full Text] [Related]
18. Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker.
Huddleston HG; Wong KK; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2005 Jan; 96(1):77-83. PubMed ID: 15589584
[TBL] [Abstract][Full Text] [Related]
19. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
[TBL] [Abstract][Full Text] [Related]
20. JAK3, STAT3 and CD3-zeta signaling proteins status in regard to the lymphocytes function in patients with ovarian cancer.
Klink M; Kielbik M; Nowak M; Bednarska K; Sulowska Z
Immunol Invest; 2012; 41(4):382-98. PubMed ID: 22221142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
